FRANKFURT, Aug 8 (Reuters) - Germany's influential

vaccine advisory panel said on Thursday that everyone in the

country who is 75-years old or more should receive one of two

new vaccines against the common respiratory infection RSV.

The panel of independent experts known as STIKO said in a

statement that one shot, either Pfizer's ( PFE ) Abrysvo or

Arexvy by GSK, should be administered ideally in

September or October before the cold season.

New pharmaceutical protection against RSV, a virus

potentially dangerous for infants and the elderly, has provided

a global sales boost for the companies that won regulatory

approval.

STIKO said in June all infants in the country should receive

AstraZeneca ( AZN ) and Sanofi's jointly owned

antibody therapy to protect them against RSV.

STIKO advice is widely followed by family doctors in

Germany, Europe's largest pharmaceutical market.

It also said that people as young as 60 with certain chronic

diseases should also get an RSV vaccine shot.

More health data will be needed to decide whether future

booster shots should be given after one vaccination, STIKO

added.